Well-differentiated carcinoma of the thyroid

Otolaryngologic Clinics of North America

Volumn 36, Issue 1, 2003, Pages 73-90

  Boone, Ryan T ^a   Fan, Chun Yang ^b   Hanna, Ehab Y ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; RADIOACTIVE IODINE; THYROTROPIN;

ANAPLASTIC CARCINOMA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CAUSE OF DEATH; CELL DIFFERENTIATION; DIFFERENTIAL DIAGNOSIS; FEMALE; GENDER; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDULLARY CARCINOMA; NECK DISSECTION; ONCOCYTOMA; RADIATION HAZARD; REVIEW; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID HORMONE RELEASE; THYROID LYMPHOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY; UNITED STATES;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADENOMA, OXYPHILIC; ADULT; BIOPSY, NEEDLE; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM STAGING; PREGNANCY; PROGNOSIS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 12244252750     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0030-6665(02)00127-5     Document Type: Review

References (91)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52(1):23-47.
2. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328(8):553-559.
3. Mazzaferri EL. Thyroid cancer and Graves' disease: the controversy ten years later. Endocrine Practice 2000;6(2):221-5.
4. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97(5):418-28.
5. Lam KY, Lo CY, Liu MC. Primary squamous cell carcinoma of the thyroid gland: an entity with aggressive clinical behaviour and distinctive cytokeratin expression profiles. Histopathology 2001;39(3):279-86.
6. Qubain SW, Nakano S, Baba M, et al. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 2002;131(3):249-56.
7. Sivanandan R, Soo KC. Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid. Br J Surg 2001;88(9):1241-4.
8. Wunderbaldinger P, Harisinghani MG, Hahn PF, et al. Cystic lymph node metastases in papillary thyroid carcinoma. Am J Roentgenol 2002;178(3):693-7.
9. Kozol RA, Geelhoed GW, Flynn SD, et al. Management of ectopic thyroid nodules. Surgery 1993;114(6):1103-7.
10. Rabinov CR, Ward PH, Pusheck T. Evolution and evaluation of lateral cystic neck masses containing thyroid tissue: "lateral aberrant thyroid" revisited. Am J Otolaryngol 1996;17(1):12-5.
11. De Jong SA, Demeter JG, Jarosz H, et al. Primary papillary thyroid carcinoma presenting as cervical lymphadenopathy: the operative approach to the "lateral aberrant thyroid". American Surgeon 1993;59(3):172-7.
12. Maceri DR, Babyak J, Ossakow SJ. Lateral neck mass. Sole presenting sign of metastatic thyroid cancer. Arch Otolaryngol Head Neck Surg 1986;112(1):47-9.
13. Watson MG, Birchall JP, Soames JV. Is 'lateral aberrant thyroid' always metastatic tumour? J Laryngol Otol 1992;106(4):376-8.
14. Moncet D, Manavela M, Cross GE, et al. Papillary carcinoma in thyroglossal duct cyst. Endocrine Practice 2001;7(6):463-6.
15. Patel SG, Escrig M, Shaha AR, et al. Management of well-differentiated thyroid carcinoma presenting within a thyroglossal duct cyst. J Surg Oncol 2002;79(3)(Suppl):134-141.
16. Pribitkin EA, Friedman O. Papillary carcinoma in a thyroglossal duct remnant. Arch Otolaryngol Head Neck Surg 2002;128(4):461-4.
17. Merritt RM, Williams MF, James TH, et al. Detection of cervical metastasis. A metaanalysis comparing computed tomography with physical examination. Arch Otolaryngol Head Neck Surg 1997;123(2):149-52.
18. Gross ND, Weissman JL, Talbot JM, et al. MRI detection of cervical metastasis from differentiated thyroid carcinoma. Laryngoscope 2001;111(11 Pt 1):1905-9.
19. Stokkel MP, de Klerk JM, Hordijk GJ. Fluorodeoxyglucose positron emission tomography, a new technique for increasing the detection rate of coincident thyroid cancer in head and neck oncology. Eur Arch Otorhinolaryngol 2000;257(10):552-4.
20. Shiga T, Tsukamoto E, Nakada K, et al. Comparison of (18)F-FDG, (131)I-Na, and (201)T1 in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001;42(3):414-9.
21. McDougall IR, Davidson J, Segall GM. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 2001;22(5):485-92.
22. Macapinlac HA. Clinical usefulness of FDG PET in differentiated thyroid cancer. J Nucl Med 2001;42(1):77-8.
23. Boyd LA, Earnhardt RC, Dunn JT, et al. Preoperative evaluation and predictive value of fine-needle aspiration and frozen section of thyroid nodules. J Am Coll Surg 1998;187(5):494-502.
24. Ogawa Y, Kato Y, Ikeda K, et al. The value of ultrasound-guided fine-needle aspiration cytology for thyroid nodules: an assessment of its diagnostic potential and pitfalls. Surg Today 2001;31(2):97-101.
25. Renshaw AA. Accuracy of thyroid fine-needle aspiration using receiver operator characteristic curves. Am J Clin Pathol 2001;116(4):477-82.
26. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104(6):947-53.
27. Cady B. Papillary carcinoma of the thyroid gland: treatment based on risk group definition. Surg Oncol Clin N Am 1998;7(4):633-44.
28. Cady B. Staging in thyroid carcinoma. Cancer 1998;83(5):844-7.
29. Davis NL, Bugis SP, McGregor GI, et al. An evaluation of prognostic scoring systems in patients with follicular thyroid cancer. Am J Surg 1995;170(5):476-80.
30. Kuriakose MA, Hicks WL Jr, Loree TR, et al. Risk group-based management of differentiated thyroid carcinoma. J R Coll Surg Edinb 2001;46(4):216-23.
31. Pasieka JL, Rotstein LE. Consensus conference on well-differentiated thyroid cancer: a summary. Can J Surg 1993;36(4):298-301.
32. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998;133(4):419-25.
33. Hay CG, Taylor WF, McConahey WM. Ipsilateral versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome novel prognostic scoring system. Surgery 1987;102:1171-8.
34. Hay I. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990;19:545-76.
35. Stojadinovic A, Ghossein RA, Hoos A, et al. Hurthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol 2001;19(10):2616-25.
36. Stojadinovic A, Hoos A, Ghossein RA, et al. Hurthle cell carcinoma: a 60-year experience. Ann Surg Oncol 2002;9(2):197-203.
37. Chow SM, Law SC, Au SK, et al. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head Neck 2002;24:670-7.
38. Salvesen H, Njolstad PR, Akslen LA, et al. Papillary thyroid carcinoma: a multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. Eur J Surg 1992;158(11-12):583-9.
39. Voutilainen PE, Multanen MM, Leppaniemi AK, et al. Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 2001;11(10): 953-957.
40. Beasley NJ, Lee J, Eski S, et al. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 2002;128(7):825-828.
41. Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82(11):3553-62.
42. Sato N, Oyamatsu M, Koyama Y, et al. Do the level of nodal disease according to the TNM classification and the number of involved cervical nodes reflect prognosis in patients with differentiated carcinoma of the thyroid gland? J Surg Oncol Suppl 1998;69(3):151-155.
43. Brierley JD, Panzarella T, Tsang RW, et al. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 1997;79(12):2414-23.
44. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9(5):421-7.
45. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocrine Practice 2000;6(6):469-76.
46. Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. Br J Surg 1996;83(12):1674-83.
47. Nasir A, Chaudhry AZ, Gillespie J, et al. Papillary microcarcinoma of the thyroid: a clinico-pathologic and prognostic review. In Vivo 2000;14(2):367-76.
48. Sugino K, Ito K Jr, Ozaki O, et al. Papillary microcarcinoma of the thyroid. J Endocrinol Invest 1998;21(7):445-8.
49. Witterick IJ, Abel SM, Noyek AM, et al. Nonpalpable occult and metastatic papillary thyroid carcinoma. Laryngoscope 1993;103(2):149-55.
50. Perez LA, Gupta PK, Mandel SJ, et al. Thyroid papillary microcarcinoma. Is it really a pitfall of fine needle aspiration cytology? Acta Cytol 2001;45(3):341-6.
51. LiVolsi VA. Pathology of the thyroid gland. 2nd edition. New York: Marcel Dekker, Inc.; 2001.
52. Pacini F, Elisei R, Capezzone M, et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid 2001;11(9):877-81.
53. Kawaura M, Pathak I, Gullane PJ, et al. Multicentricity in papillary thyroid carcinoma: analysis of predictive factors. J Otolaryngol 2001;30(2):102-5.
54. Jobran R, Baloch ZW, Aviles V, et al. Tall cell papillary carcinoma of the thyroid: metastatic to the pancreas. Thyroid 2000;10(2):185-7.
55. Shimizu M, Hirokawa M, Manabe T. Tall cell variant of papillary thyroid carcinoma with foci of columnar cell component. Virchows Arch 1999;434(2):173-5.
56. Shaha AR. Management of the neck in thyroid cancer. Otolaryngol Clin North Am 1998;31(5):823-31.
57. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 2000;7(3):229-39.
58. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997;7(2):265-71.
59. DeGroot LJ, Kaplan EL, Straus FH, et al. Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg 1994;18(1):123-130.
60. Duren M, Yavuz N, Bukey Y, et al. Impact of initial surgical treatment on survival of patients with differentiated thyroid cancer: experience of an endocrine surgery center in an iodine-deficient region. World J Surg 2000;24(11):1290-4.
61. Ogren FP. Under most circumstances, thyroid lobectomy is appropriate for low-risk patients with papillary cancer of the thyroid. Arch Otolaryngol Head Neck Surg 2001;127(4):461-2.
62. Shaha AR, Shah JP, Loree TR. Patterns of failure in differentiated carcinoma of the thyroid based on risk groups. Head Neck 1998;20(1):26-30.
63. McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991;162(4):353-6.
64. Noguchi S, Murakami N. The value of lymph-node dissection in patients with differentiated thyroid cancer. Surg Clin North Am 1987;67(2):251-61.
65. Shaha AR. Invited commentary: minimally invasive follicular thyroid carcinoma. Surgery 2001;130(1):119-20.
66. Ballantyne AJ. Neck dissection for thyroid cancer. Semin Surg Oncol 1991;7(2):100-6.
67. Ohshima A, Yamashita H, Noguchi S, et al. Indications for bilateral modified radical neck dissection in patients with papillary carcinoma of the thyroid. Arch Surg 2000;135(10):1194-1199.
68. Mazzaferri EL, Robyn J. Postsurgical management of differentiated thyroid carcinoma. Otolaryngol Clin North Am 1996;29(4):637-62.
69. Edmonds CJ, Hayes S, Kermode JC, et al. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 1977;50(599):799-807.
70. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000;10(9):767-78.
71. Giovanni V, Arianna LG, Antonio C, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf) 2002;56(2):247-52.
72. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001;11(9):865-9.
73. O'Connell ME, A'Hern RP, Harmer CL. Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. Eur J Cancer 1994;30A(6):733-9.
74. Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988;14(6):1063-75.
75. Benker G, Olbricht T, Reinwein D, et al. Survival rates in patients with differentiated thyroid carcinoma. Influence of postoperative external radiotherapy. Cancer 1990;65(7):1517-20.
76. Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996;77(1):172-80.
77. Phlips P, Hanzen C, Andry G, et al. Postoperative irradiation for thyroid cancer. Eur J Surg Oncol 1993;19(5):399-404.
78. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56(9):2155-60.
79. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986;70(3):405-7.
80. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60(10):2372-5.
81. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997;4(4):328-33.
82. Segal K, Arad-Cohen A, Mechlis S, et al. Cancer of the thyroid in children and adolescents. Clinical Otolaryngol Allied Sci 1997;22(6):525-8.
83. Vassilopoulou-Sellin R, Goepfert H, Raney B, et al. Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. Head Neck 1998;20(6):549-55.
84. Vassilopoulou-Sellin R. Long-term outcome of children with papillary thyroid cancer. Surgery 2001;129(6):769.
85. Welch Dinauer CA, Tuttle RM, Robie DK, et al. Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf) 1998;49(5):619-28.
86. Wiersinga WM. Thyroid cancer in children and adolescents-consequences in later life. J Ped Endocrin 2001;14(Suppl 5):1289-98.
87. Hallwirth U, Flores J, Kaserer K, et al. Differentiated thyroid cancer in children and adolescents: the importance of adequate surgery and review of literature. Eur J Pediatr Surg 1999;9(6):359-63.
88. Moosa M, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab 1997;82(9):2862-6.
89. McClellan DR, Francis GL. Thyroid cancer in children, pregnant women, and patients with Graves' disease. Endocrinol Metab Clin North Am 1996;25(1):27-48.
90. Herzon FS, Morris DM, Segal MN, et al. Coexistent thyroid cancer and pregnancy. Arch Otolaryngol Head Neck Surg 1994;120(11):1191-3.
91. Vini L, Hyer S, Pratt B, et al. Management of differentiated thyroid cancer diagnosed during pregnancy. Eur J Endocrinol 1999;140(5):404-6.